Reporting owner · CIK 0001117167

Casamento Charles J

SEC Form 4 history for the last 180 days across 1 company, 13 transactions and 1 filing.

DIREton Pharmaceuticals, Inc.
Open-market transaction mix0% buys0 buys · 5 sales

Period: Last 180 days

Trade dates in this period: Nov 10, 2026 – Nov 10, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$5.35M5 sales
Net value−$5.35MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Casamento Charles J transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$197kView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$2.28MView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$1.50MView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$961kView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$410kView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$79.4kView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$169kView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$98.1kView disclosure →
ETONEton Pharmaceuticals, Inc.
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$91.4kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Eton Pharmaceuticals, Inc. on Nov 10, 2026 valued at $197,025.16.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Nov 202605$0$5,345,071.68−$5,345,071.68

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$1.07M
Median P/S size$961k
Direct13
Indirect0
Nov 10, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

9 observations · Nov 10, 2026 – Nov 10, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 10, 20260 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 10, 202612,500Nov 10, 2026View transaction
Nov 10, 202639,900Nov 10, 2026View transaction
Nov 10, 202659,555Nov 10, 2026View transaction
Nov 10, 202680,555Nov 10, 2026View transaction
Nov 10, 202674,175Nov 10, 2026View transaction
Nov 10, 202659,460Nov 10, 2026View transaction
Nov 10, 202636,859Nov 10, 2026View transaction
Nov 10, 20262,903Nov 10, 2026View transaction
Nov 10, 20260Nov 10, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Casamento Charles J Insider Activity FAQ

SEC Form 4 context

Who is Casamento Charles J?

Casamento Charles J is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001117167.

Which companies has Casamento Charles J reported transactions for?

Eton Pharmaceuticals, Inc., First Wave BioPharma, Inc.

When was Casamento Charles J's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Casamento Charles J's latest insider sale?

The insider reported a sale at Eton Pharmaceuticals, Inc. on Nov 10, 2026 valued at $197,025.16.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.